Massachusetts is currently home to 3204 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Kisspeptin Administration Subcutaneously to Patients With IHH
NCT05896293
Recruiting
The goal of this study is to see whether kisspeptin, a naturally occurring hormone, can stimulate the release of other reproductive hormones in men and women with idiopathic hypogonadotropic hypogonadism (IHH). The investigators are also examining whether kisspeptin can help women release eggs from their ovaries. Kisspeptin will be administered SC for two weeks in a pulsatile fashion. Ultrasound monitoring of ovarian follicular growth (for women) and frequent blood sampling (every 10 minutes for... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Hypogonadotropic Hypogonadism
Register for Updates
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
NCT05887492
Recruiting
The goal of this interventional clinical trial is to learn about TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known STK11 mutation. The main question\[s\] it aims to answer are: * the recommended dose for Phase 2 * to evaluate the safety and tolerability of the combination therapy * to determine the pharmacokinetics of TNG260 * to evaluate the initial antineoplastic activity Participants will receive study treatment until they exp... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Non Small Cell Lung Cancer, Solid Tumors, Adult, Lung Cancer, Lung Adenocarcinoma
Register for Updates
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
NCT05877599
Recruiting
Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Research Site, Boston, Massachusetts
Conditions: Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma, Breast Cancer, Other Solid Tumors, Ovarian Cancer
Register for Updates
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia
NCT05778188
Recruiting
Hypoxic-ischemic encephalopathy (HIE) affects approximately 4,000 to 12,000 persons annually in the United States. Mortality from HIE has been reported up to 60%, with at least 25% of survivors left with significant neurocognitive disability. Despite this vital unmet medical need, no pharmacological adjunct or alternative therapy has proven beneficial in improving outcomes in neonatal HIE. RLS-0071 is a novel peptide being developed for the treatment of neonatal HIE. This study is designed to e... Read More
Gender:
ALL
Ages:
10 hours and below
Trial Updated:
07/22/2025
Locations: Study Site 002, Boston, Massachusetts
Conditions: Hypoxic-Ischemic Encephalopathy
Register for Updates
Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders
NCT05633966
Recruiting
The goal of this study is to see whether kisspeptin, a naturally occurring hormone, can stimulate the release of other reproductive hormones in women with hypothalamic amenorrhea (HA). The investigators are also examining whether kisspeptin can help women release eggs from their ovaries. Kisspeptin will be administered subcutaneously (SC) for two weeks in a pulsatile fashion. Ultrasound monitoring of ovarian follicular growth and frequent blood sampling (every 10 minutes for up to two hours) wil... Read More
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
07/22/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Hypothalamic Amenorrhea, Hypogonadotropic Hypogonadism
Register for Updates
Efficacy of Suvorexant in the Treatment of Insomnia in Midlife Women With Pre-Diabetes
NCT05593653
Recruiting
The aim of this study is to determine if suvorexant can help treat the severity of insomnia in midlife women who are pre-diabetic.
Gender:
FEMALE
Ages:
Between 40 years and 65 years
Trial Updated:
07/22/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Insomnia, Diabetes, Menopause
Register for Updates
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
NCT05549297
Recruiting
The purpose of this study is to evaluate the efficacy and safety of tebentafusp-based regimens, including tebentafusp monotherapy and in combination with anti-PD1 vs investigator choice (including clinical trials of investigational agents, salvage therapy per local standard of care \[SoC\], best supportive care \[BSC\] on protocol survivor follow up) in patients with advanced non-ocular melanoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Advanced Melanoma
Register for Updates
Study of SGR-1505 in Mature B-Cell Neoplasms
NCT05544019
Recruiting
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia, MALT Lymphoma, Follicular Lymphoma, Pediatric-Type Follicular Lymphoma, IRF4 Gene Rearrangement, EBV-Positive DLBCL, Nos, Burkitt Lymphoma, Plasmablastic Lymphoma, High-grade B-cell Lymphoma, Primary Cutaneous Follicle Center Lymphoma, Primary Effusion Lymphoma, Mantle Cell Lymphoma, DLBCL Germinal Center B-Cell Type, Primary Mediastinal Large B Cell Lymphoma, T-Cell/Histiocyte Rich Lymphoma, ALK-Positive Large B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Splenic Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, Nodal Marginal Zone Lymphoma, HHV8-Positive DLBCL, Nos, Lymphoplasmacytic Lymphoma, Duodenal-Type Follicular Lymphoma
Register for Updates
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054
Recruiting
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Breast Neoplasms
Register for Updates
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
NCT05237258
Recruiting
This research study is evaluating whether primary palliative care is an alternative strategy to specialty palliative care for improving quality of life, symptoms, mood, coping, and end of life outcomes in patients with acute myeloid leukemia (AML).
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
07/22/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Relapsed Adult AML, Primary Refractory Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia
Register for Updates
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
NCT05099770
Recruiting
The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys in participants with T2DM and CKD.
Gender:
ALL
Ages:
Between 30 years and 80 years
Trial Updated:
07/22/2025
Locations: Holyoke Medical Center, Springfield, Massachusetts
Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Diseases
Register for Updates
Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors
NCT05007782
Recruiting
This is a first-in-human (FIH) study to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of denikitug (also known as GS-1811) as monotherapy and in combination with zimberelimab in participants with advanced solid tumors. This study will be conducted in 6 parts (Parts A, B, and E: monotherapy, Parts C and D: combination therapy, and Part F for both monotherapy and combination therapy) in participants with advanced... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Advanced Solid Tumor
Register for Updates